The Vascular-Disrupting Agent Combretastatin Impairs Splitting and Sprouting Forms of Physiological Angiogenesis

Microcirculation

Volumn 19, Issue 4, 2012, Pages 296-305

  Hussain, Arif ^a   Steimle, Manuel ^b   Hoppeler, Hans ^b   Baum, Oliver ^b   Egginton, Stuart ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Blood flow; Capillaries; Electron microscopy; Stereology

Indexed keywords

ACTIN; CA 4 F; COMBRETASTATIN; PRAZOSIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; FEMORAL ARTERY FLOW; FILOPODIUM; HYPEREMIA; LAMELLIPODIUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; ULTRASTRUCTURE;

ACTINS; ANIMALS; BIBENZYLS; BLOOD FLOW VELOCITY; FEMORAL ARTERY; HYPEREMIA; MALE; MICE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RHO GTP-BINDING PROTEINS; TUBULIN MODULATORS;

MUS;

EID: 84860250385     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/j.1549-8719.2012.00160.x     Document Type: Article

References (38)

1. Baum O, Da Silva-Azevedo L, Willerding G, Wockel A, Planitzer G, Gossrau R, Pries AR, Zakrzewicz A. Endothelial NOS is main mediator for shear stress-dependent angiogenesis in skeletal muscle after prazosin administration. Am J Physiol Heart Circ Physiol 287: H2300-H2308, 2004.
2. Bohle AS, Leuschner I, Kalthoff H, Henne-Bruns D. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer 87: 838-843, 2000.
3. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-195, 1999.
4. Da Silva-Azevedo L, Baum O, Zakrzewicz A, Pries AR. Vascular endothelial growth factor is expressed in endothelial cells isolated from skeletal muscles of nitric oxide synthase knockout mice during prazosin-induced angiogenesis. Biochem Biophys Res Commun 297: 1270-1276, 2002.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
6. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45: 136-139, 1982.
7. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Arch 457: 963-977, 2009.
8. Egginton S. Physiological factors influencing capillary growth. Acta Physiol 202: 1633-1638, 2011.
9. Egginton S, Hudlicka O, Glover M. Fine structure of capillaries in ischaemic and non ischaemic rat striated muscle. Effect of torbafylline. Int J Microcirc Clin Exp 12: 33-44, 1993.
10. Egginton S, Zhou AL, Brown MD, Hudlicka O. Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res 49: 634-646, 2001.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
12. Fryer BH, Field J. Rho, Rac, Pak and angiogenesis: old roles and newly identified responsibilities in endothelial cells. Cancer Lett 229: 13-23, 2005.
13. Fulgenzi G, Graciotti L, Collis MG, Hudlicka O. The effect of alpha 1 adrenoceptor antagonist prazosin on capillary supply, blood flow and performance in a rat model of chronic muscle ischaemia. Eur J Vasc Endovasc Surg 16: 71-77, 1998.
14. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21: 93-102, 2001.
15. Gundersen GG, Cook TA. Microtubules and signal transduction. Curr Opin Cell Biol 11: 81-94, 1999.
16. Haas TL, Milkiewicz M, Davis SJ, Zhou AL, Egginton S, Brown MD, Madri JA, Hudlicka O. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 279: H1540-H1547, 2000.
17. van Hinsbergh VW, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 79: 391-411, 1997.
18. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90: 1026-1038, 1999.
19. Hueck IS, Rossiter K, Artmann GM, Schmid-Schonbein GW. Fluid shear attenuates endothelial pseudopodia formation into the capillary lumen. Microcirculation 15: 531-542, 2008.
20. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8: 309-316, 2008.
21. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-2069, 2002.
22. Kumar A, Murphy R, Robinson P, Wei L, Boriek AM. Cyclic mechanical strain inhibits skeletal myogenesis through activation of focal adhesion kinase, Rac-1 GTPase, and NF-kappaB transcription factor. FASEB J 18: 1524-1535, 2004.
23. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116: 1859-1871, 2010.
24. van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today 16: 219-228, 2011.
25. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 23: 211-217, 2003.
26. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 83: 811-816, 2000.
27. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50: 119-131, 1987.
28. Pettit GR, Temple C Jr., Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10: 299-309, 1995.
29. Rodriguez OC, Schaefer AW, Mandato CA, Forscher P, Bement WM, Waterman-Storer CM. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat Cell Biol 5: 599-609, 2003.
30. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21: 2815-2822, 2003.
31. Schwartz EL. Anti-vascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601, 2009.
32. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 18: 189-197, 2009.
33. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413-6422, 2001.
34. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634, 1999.
35. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115: 2992-3006, 2005.
36. Williams JL, Cartland D, Hussain A, Egginton S. A differential role for nitric oxide in two forms of physiological angiogenesis in mouse. J Physiol 570: 445-454, 2006.
37. Zhou AL, Egginton S, Brown MD, Hudlicka O. Capillary growth in overloaded, hypertrophic adult rat skeletal muscle: an ultrastructural study. Anat Rec 252: 49-63, 1998.
38. Zhou A, Egginton S, Hudlicka O, Brown MD. Internal division of capillaries in rat skeletal muscle in response to chronic vasodilator treatment with alpha1-antagonist prazosin. Cell Tissue Res 293: 293-303, 1998.